CA3228411A1 - Sulfonamide derivative, preparation method therefor and medical use thereof - Google Patents

Sulfonamide derivative, preparation method therefor and medical use thereof Download PDF

Info

Publication number
CA3228411A1
CA3228411A1 CA3228411A CA3228411A CA3228411A1 CA 3228411 A1 CA3228411 A1 CA 3228411A1 CA 3228411 A CA3228411 A CA 3228411A CA 3228411 A CA3228411 A CA 3228411A CA 3228411 A1 CA3228411 A1 CA 3228411A1
Authority
CA
Canada
Prior art keywords
general formula
cancer
compound represented
group
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3228411A
Other languages
English (en)
French (fr)
Inventor
Xiaomin Zhang
Weimin Hu
Feng He
Weikang Tao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Hengrui Pharmaceutical Co Ltd
Jiangsu Hengrui Pharmaceutical Co Ltd
Original Assignee
Shanghai Hengrui Pharmaceutical Co Ltd
Jiangsu Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Hengrui Pharmaceutical Co Ltd, Jiangsu Hengrui Pharmaceutical Co Ltd filed Critical Shanghai Hengrui Pharmaceutical Co Ltd
Publication of CA3228411A1 publication Critical patent/CA3228411A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3228411A 2021-08-10 2022-08-10 Sulfonamide derivative, preparation method therefor and medical use thereof Pending CA3228411A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN202110913249 2021-08-10
CN202110913249.1 2021-08-10
CN202111142090.4 2021-09-28
CN202111142090 2021-09-28
CN202111500231 2021-12-09
CN202111500231.5 2021-12-09
PCT/CN2022/111395 WO2023016484A1 (zh) 2021-08-10 2022-08-10 磺酰胺衍生物、其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
CA3228411A1 true CA3228411A1 (en) 2023-02-16

Family

ID=85200573

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3228411A Pending CA3228411A1 (en) 2021-08-10 2022-08-10 Sulfonamide derivative, preparation method therefor and medical use thereof

Country Status (10)

Country Link
US (1) US20250145637A1 (enExample)
EP (1) EP4385989A4 (enExample)
JP (1) JP2024529068A (enExample)
KR (1) KR20240046530A (enExample)
CN (1) CN117597341A (enExample)
AU (1) AU2022325367A1 (enExample)
CA (1) CA3228411A1 (enExample)
MX (1) MX2024001777A (enExample)
TW (1) TW202321263A (enExample)
WO (1) WO2023016484A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024201334A1 (en) * 2023-03-30 2024-10-03 Pfizer Inc. Kat6a as a predictive biomarker for treatment with a kat6a inhibitor and methods of treatment thereof
WO2025136811A1 (en) * 2023-12-18 2025-06-26 Ideaya Biosciences, Inc. Chemical compounds and uses thereof

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023088233A1 (en) 2021-11-16 2023-05-25 Insilico Medicine Ip Limited Lysine acetyltransferase 6a (kat6a) inhibitors and uses thereof
CA3241874A1 (en) * 2021-12-13 2023-06-22 Aurigene Oncology Limited Fused benzoisoxazolyl compounds as kat6a inhibitors
CN116621859A (zh) * 2022-02-18 2023-08-22 山东轩竹医药科技有限公司 三并环类kat6抑制剂
AU2023241822A1 (en) 2022-03-28 2024-09-26 Isosterix, Inc. Inhibitors of the myst family of lysine acetyl transferases
AU2024217108A1 (en) * 2023-02-10 2025-09-18 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Crystalline form of sulfonamide derivative and preparation method therefor
CN120917003A (zh) 2023-03-16 2025-11-07 奥列马制药公司 酰基磺酰胺kat6a抑制剂
WO2025007873A1 (zh) 2023-07-04 2025-01-09 上海齐鲁制药研究中心有限公司 Kat6抑制剂
WO2025098417A1 (zh) * 2023-11-08 2025-05-15 再和医药科技（苏州）有限公司 磺酰胺类化合物及其应用
US20250161289A1 (en) * 2023-11-10 2025-05-22 Prelude Therapeutics Incorporated KAT6 Targeting Compounds
WO2026086887A1 (zh) * 2024-10-23 2026-04-30 江苏恒瑞医药股份有限公司 Kat6抑制剂与ar protac的联合

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750542A (en) * 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
ES2188584T3 (es) * 1991-03-28 2003-07-01 Eisai Co Ltd Derivados heterociclicos de amina.
WO2002074746A1 (en) * 2001-03-16 2002-09-26 Yamanouchi Pharmaceutical Co., Ltd. Benzazepine derivatives
AU2003215380B2 (en) * 2002-02-22 2008-10-02 Bayer Pharmaceuticals Corporation Fused tricyclic heterocycles useful for treating hyper-proliferative disorders
AU2006281803B9 (en) * 2005-08-18 2013-05-30 Genmab A/S Therapy with CD4 binding peptides and radiation
CN105492430B (zh) * 2013-03-15 2017-10-10 基因泰克公司 取代的苯并噁唑及其使用方法
WO2015102929A1 (en) * 2013-12-30 2015-07-09 Novartis Ag Tricyclic sulfonamide derivatives
TWI705967B (zh) * 2014-03-20 2020-10-01 美商卡佩拉醫療公司 苯并咪唑衍生物及其醫藥組合物及使用方法
GB201510019D0 (en) 2015-06-09 2015-07-22 Cancer Therapeutics Crc Pty Ltd Compounds
US10787430B2 (en) 2016-06-17 2020-09-29 Fronthera U.S. Pharmaceuticals Llc Hemoglobin modifier compounds and uses thereof
GB201713962D0 (en) 2017-08-31 2017-10-18 Ctxt Pty Ltd Compounds
US11685732B2 (en) 2017-11-29 2023-06-27 Epizyme, Inc. MYST family histone acetyltransferase inhibitors
GB201810092D0 (en) * 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
WO2020048548A1 (zh) * 2018-09-07 2020-03-12 正大天晴药业集团股份有限公司 一种作用于crbn蛋白的三并环类化合物
EA202092908A1 (ru) 2018-09-28 2021-05-14 Праксис Пресижн Медсинз, Инк. Модуляторы ионных каналов
CN114072394A (zh) 2019-04-25 2022-02-18 拜耳股份公司 用于治疗癌症的酰基磺酰胺
PH12021553107A1 (en) * 2019-06-18 2022-08-01 Ctxt Pty Ltd Benzisoxazole sulfonamide derivatives
AU2020295006B2 (en) * 2019-06-19 2023-11-09 Ctxt Pty Ltd Cycloalkyl and heterocycloalkyl benzisoxazole sulfonamide derivatives

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024201334A1 (en) * 2023-03-30 2024-10-03 Pfizer Inc. Kat6a as a predictive biomarker for treatment with a kat6a inhibitor and methods of treatment thereof
WO2025136811A1 (en) * 2023-12-18 2025-06-26 Ideaya Biosciences, Inc. Chemical compounds and uses thereof

Also Published As

Publication number Publication date
WO2023016484A1 (zh) 2023-02-16
EP4385989A1 (en) 2024-06-19
AU2022325367A1 (en) 2024-02-08
JP2024529068A (ja) 2024-08-01
EP4385989A4 (en) 2024-12-18
US20250145637A1 (en) 2025-05-08
KR20240046530A (ko) 2024-04-09
TW202321263A (zh) 2023-06-01
MX2024001777A (es) 2024-02-29
CN117597341A (zh) 2024-02-23

Similar Documents

Publication Publication Date Title
EP4385989A1 (en) Sulfonamide derivative, preparation method therefor and medical use thereof
CN115448910B (zh) 一种哒嗪类衍生物抑制剂、其制备方法和应用
JP6403172B2 (ja) ピリジンのケトン誘導体、それらの製造方法、およびそれらの医薬適用
JP2020510012A (ja) ヘテロアリール［４，３−ｃ］ピリミジン−５−アミン誘導体、その製造方法、およびその医薬の使用
CN114149423B (zh) 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用
JP2023145547A (ja) Ｃｄ７３阻害剤、その製造方法と応用
TW201934554A (zh) 吡唑并[1,5-a][1,3,5]三<img align="absmiddle" height="18px" width="27px" file="d10999.TIF" alt="其他非圖式 d10999.TIF" img-content="tif" orientation="portrait" inline="yes"></img>-2-胺類衍生物、其製備方法及其在醫藥上的應用
TW202102505A (zh) 吡咯并雜環類衍生物、其製備方法及其在醫藥上的應用
JP7793763B2 (ja) Ｔｙｋ２／ｊａｋ１シュードキナーゼドメイン阻害剤としての化合物ならびに合成および使用方法
AU2024205090A1 (en) Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
WO2020011220A1 (zh) 杂芳基类衍生物、其制备方法及其在医药上的应用
KR20260006574A (ko) Kcc2 강화제 및 이의 용도
CN112996783B (zh) 2-氨基嘧啶类衍生物、其制备方法及其在医药上的应用
CN112574212B (zh) 一种嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用
CN107428762B (zh) 酞嗪酮衍生物、其制备方法及用途
AU2024319888A1 (en) Heteroaryl compound, preparation method therefor, and use thereof in medicine
CN115611877A (zh) 磺酰胺类化合物、其制备方法及其在医药上的应用
JP2023536442A (ja) オキサアザスピロ環系誘導体、その調製方法及びその医薬的応用
EA053325B1 (ru) Сульфонамидное производное, способ его получения и его применение в медицине
CN115835863B (zh) 氧杂氮杂双环类衍生物、其制备方法及其在医药上的应用
CN110684020B (zh) 2-胺基嘧啶类衍生物、其制备方法及其在医药上的应用
CN118791498A (zh) 四环类化合物、其制备方法及其在医药上的应用
CN118978521A (zh) 并环化合物制备方法及应用
CA3300208A1 (en) Heteroaryl compound, preparation method therefor, and use thereof in medicine
CN113754678A (zh) 二氢硫代色烯并吡唑类衍生物、其制备方法及其在医药上的应用

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240724

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240724

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250725

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250828